Visikol is a drug discovery service company based in North Brunswick, NJ. The company focuses on accelerating drug discovery through quantitative histopathology and its patented Visikol® HISTO™ tissue-clearing technology. Visikol® HISTO™ transforms tissues into three-dimensional data sets that can be mined for actionable insights. When paired with fluorescent labeling and 3D microscopy, the technology allows 3D cell culture models and whole tissues to be imaged in their entirety. The company intends to use the newly secured funding to develop bio-imaging services for drug discovery, including 3D in vitro cell culture assays, and to expand its commercial operations. Leadership includes CEO Dr. Michael Johnson and COO Nick Crider; the amount raised was undisclosed. Visikol is a New Brunswick, N.J.-based developer of a nondestructive optical clearing agent, Visikol®, designed to reduce light scattering and enable high-resolution imaging of biological tissues. The company holds exclusive rights to Visikol® through a license from Rutgers University. Visikol plans to use the $225K SBIR grant from the National Science Foundation to further develop its skeletal visualization technology platform to improve developmental and reproductive toxicology (DART) studies. The company was co-founded by Michael Johnson (CEO), Nick Crider (COO) and Tom Villani (CSO). Visikol was originally funded by Foundation Venture Capital Group Inc. No operating metrics were disclosed in the article. Visikol, Inc. develops a patent-pending biological clearing agent that penetrates tissue and renders it transparent without causing structural damage. The technology enables visualization of tissues in three dimensions and has applications in toxicology, pre-clinical drug development, clinical diagnostics, basic research and plant biology. The Visikol technology was invented by Tom Villani along with Rutgers professors Drs. James Simon and Adolfina Koroch. Visikol has exclusively licensed worldwide rights to the technology through an agreement with Rutgers University. The company was founded by Michael Johnson (CEO), Nick Crider (COO) and Tom Villani (CSO) and is based in New Brunswick, N.J. The company recently raised external funding to support development and commercialization of the technology.

Total raised

$1M

Funding rounds

3

Latest round

Grant

Latest activity

Jul 2016